Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olverembatinib + blinatumomab + chemotherapy
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intrathecal, Intravenous, Oral, Subcutaneous
01
Overview
olverembatinib + blinatumomab + chemotherapy is a combination regimen consisting of olverembatinib (a third-generation BCR-ABL1 tyrosine kinase inhibitor), blinatumomab (a bispecific CD19-directed CD3 T-cell engager), and chemotherapy. This combination is primarily investigated for the treatment of Philadelphia chromosome-positive (Ph+) leukemia, including Ph+ acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) in lymphoid blast phase (CML-LBP), particularly in cases with central nervous system (CNS) involvement or resistance to prior tyrosine kinase inhibitors. Olverembatinib targets BCR-ABL1 (including the T315I mutation), blinatumomab recruits T cells to destroy CD19-positive B-lineage leukemia cells, and chemotherapy provides cytotoxic effects to eradicate rapidly dividing cancer cells.
- Other names
- HQP1351 + blinatumomab + chemotherapyolverembatinib + blinatumomab + chemotherapy奥雷巴替尼 + 贝林妥欧单抗 + 化疗耐立克 + blinatumomab + chemotherapy耐立克 + 贝林妥欧单抗 + 化疗
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on olverembatinib + blinatumomab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olverembatinib + blinatumomab + chemotherapy.